Financings in Brief: SangStat Medical
This article was originally published in The Gray Sheet
Executive Summary
SangStat Medical: Organ transplantation firm plans public offering of 2 mil. shares of common stock. Net proceeds from the offering will be used "primarily for continued research and development, working capital and other general corporate purposes," the company says. SangStat, which filed a registration statement for the offering with SEC Feb. 9, announced Feb. 11 that its research, development and regulatory affairs spending increased 37% to $6.6 mil. in 1995. The company reported a net loss for the year of $8.7 mil. on total revenues of $3.8 mil., comparing to a $5.5 mil. loss on $3.7 mil. in revenues during 1994. Underwriters for the offering -- Hambrecht & Quist, Montgomery Securities, and Jeffries & Company -- have an option to purchase up to 300,000 additional shares to cover over-allotments...
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.